Company intelligence / Profile preview
DelNova
San Diego, California, United Statesdelnova.net ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
DelNova is developing ReViVox, a patent-pending product for rescuing complications caused by off-target muscle paralysis following aesthetic and medical neurotoxin therapies, specifically botulinum-Type A toxins.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculesDrug delivery technology
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
MyologicaMBHBAtheln
Beyond the preview
Go deeper on DelNova.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DelNova.